Skip to main content
SpringerLink
Log in

Collagen Vascular Disease

  • Chapter
  • First Online:
Immunology of the Skin

  • 2120 Accesses

Abstract

Collagen vascular diseases (CVDs) are a heterogeneous group of multisystem autoimmune disorders characterized by the presence of autoantibodies. It is generally accepted that the initiation and progression of CVDs, including lupus erythematosus, systemic sclerosis, and dermatomyositis, are caused by the complex interplay between environmental and intrinsic factors. The presence of autoantibodies and autoantigens derived from dying cells, such as keratinocytes in cutaneous lupus erythematosus and dermatomyositis and endothelial cells in systemic sclerosis, is a common pathological feature shared among these diseases, which leads to the activation of interferon-dependent signalings because immune complexes consisting of autoantibodies and autoantigens promote type I interferon production especially from plasmacytoid dendritic cells. Type I interferon potentially induces autoimmunity by activating innate and adaptive immunity. In addition, interferon directly induces apoptosis as well as vascular damage, two histologic hallmarks of CVDs in the skin. Note that recent progress provides new insights into the better understanding of the disease-specific pathological process connecting the initial events, cell death of keratinocytes or endothelial cells, with the progressive tissue damage via innate and adaptive immune responses. In this chapter, the role of skin immunology in the pathogenesis of cutaneous lupus erythematosus, scleroderma, and dermatomyositis is overviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Allanore Y, Saad M, Dieudé P et al (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7:e1002091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Asano Y, Ihn H, Yamane K et al (2005) Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175:7708–7718

    Article  CAS  PubMed  Google Scholar 

  3. Asano Y, Ihn H, Yamane K et al (2005) Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 52:2897–2905

    Article  CAS  PubMed  Google Scholar 

  4. Asano Y, Ihn H, Yamane K et al (2006) Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 168:499–510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Asano Y, Ihn H, Yamane K et al (2004) Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 113:253–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Asano Y, Ihn H, Yamane K et al (2004) Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 164:1275–1292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676

    Article  CAS  PubMed  Google Scholar 

  8. Blomberg S, Eloranta ML, Cederblad B et al (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10:484–490

    Article  CAS  PubMed  Google Scholar 

  9. Chizzolini C (1999) T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 21:431–450

    Article  CAS  PubMed  Google Scholar 

  10. Chizzolini C, Parel Y, De Luca C et al (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604

    Article  CAS  PubMed  Google Scholar 

  11. Chizzolini C, Rezzonico R, Ribbens C et al (1998) Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 41:2039–2047

    Article  CAS  PubMed  Google Scholar 

  12. Church LD, Cook GP, McDermott MF (2008) Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 4:34–42

    Article  CAS  PubMed  Google Scholar 

  13. Espinosa A, Dardalhon V, Brauner S et al (2009) Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 206:1661–1671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Espinosa A, Hennig J, Ambrosi A et al (2011) Anti-Ro52 autoantibodies from patients with Sjögren’s syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem 286:36478–36491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Espinosa A, Zhou W, Ek M et al (2006) The Sjogren’s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176:6277–6285

    Article  CAS  PubMed  Google Scholar 

  16. Flier J, Boorsma DM, van Beek PJ et al (2001) Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194:398–405

    Article  CAS  PubMed  Google Scholar 

  17. Frank MB, Itoh K, Fujisaku A et al (1993) The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms. Am J Hum Genet 52:183–191

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Fu Q, Zhao J, Qian X et al (2011) Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63:749–754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Giacomelli R, Matucci-Cerinic M, Cipriani P et al (1998) Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41:327–334

    Article  CAS  PubMed  Google Scholar 

  20. Graham RR, Kozyrev SV, Baechler EC et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555

    Article  CAS  PubMed  Google Scholar 

  21. Grassi M, Capello F, Bertolino L et al (2009) Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol 34:910–914

    Article  CAS  PubMed  Google Scholar 

  22. Gruschwitz M, Müller PU, Sepp N et al (1990) Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 94:197–203

    Article  CAS  PubMed  Google Scholar 

  23. Hamaguchi Y, Kuwana M, Hoshino K et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398

    Article  CAS  PubMed  Google Scholar 

  24. Higgs R, Lazzari E, Wynne C et al (2010) Self protection from anti-viral responses – Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral toll-like receptors. PLoS One 5:e11776

    Article  PubMed  PubMed Central  Google Scholar 

  25. Higgs R, Ní Gabhann J, Ben Larbi N et al (2008) The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 181:1780–1786

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hill MB, Phipps JL, Cartwright RJ et al (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ihn H, Sato S, Fujimoto M et al (1997) Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270–1275

    Article  CAS  PubMed  Google Scholar 

  28. Ihn H, Sato S, Fujimoto M et al (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192

    Article  CAS  PubMed  Google Scholar 

  29. Järvinen TM, Hellquist A, Koskenmies S et al (2010) Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol 19:123–131

    Article  PubMed  Google Scholar 

  30. Kahaleh MB, Fan PS, Otsuka T (1999) Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 91:188–195

    Article  CAS  PubMed  Google Scholar 

  31. Kalogerou A, Gelou E, Mountantonakis S et al (2005) Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64:1233–1235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kim D, Peck A, Santer D et al (2008) Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58:2163–2173

    Article  CAS  PubMed  Google Scholar 

  33. Kim JS, Bashir MM, Werth VP (2012) Gottron’s papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 132:1825–1832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kim JS, Werth VP (2011) Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem 59:780–790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kong HJ, Anderson DE, Lee CH et al (2007) Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 179:26–30

    Article  CAS  PubMed  Google Scholar 

  36. Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279–289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kuhn A, Herrmann M, Kleber S et al (2006) Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 54:939–950

    Article  PubMed  Google Scholar 

  38. Kulozik M, Hogg A, Lankat-Buttgereit B et al (1990) Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917–922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2005) Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24:111–116

    Article  PubMed  Google Scholar 

  40. Loetscher M, Gerber B, Loetscher P et al (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963–969

    Article  CAS  PubMed  Google Scholar 

  41. Magro CM, Segal JP, Crowson AN et al (2010) The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 37:659–671

    Article  PubMed  Google Scholar 

  42. Matsushita T, Hasegawa M, Hamaguchi Y et al (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284

    CAS  PubMed  Google Scholar 

  43. Mavalia C, Scaletti C, Romagnani P et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Meller S, Winterberg F, Gilliet M et al (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52:1504–1516

    Article  CAS  PubMed  Google Scholar 

  45. Mimura Y, Ihn H, Jinnin M et al (2005) Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol 166:1451–1463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Muñoz LE, Lauber K, Schiller M et al (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289

    Article  PubMed  Google Scholar 

  47. Nakashima T, Jinnin M, Yamane K et al (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188:3573–3583

    Article  CAS  PubMed  Google Scholar 

  48. Nishijima C, Hayakawa I, Matsushita T et al (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357–363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Oke V, Vassilaki I, Espinosa A et al (2009) High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J Invest Dermatol 129:2000–2010

    Article  CAS  PubMed  Google Scholar 

  50. Prescott RJ, Freemont AJ, Jones CJ et al (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263

    Article  CAS  PubMed  Google Scholar 

  51. Querfeld C, Eckes B, Huerkamp C et al (1999) Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 21:13–22

    Article  CAS  PubMed  Google Scholar 

  52. Radstake TR, Gorlova O, Rueda B et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rhodes DA, Ihrke G, Reinicke AT et al (2002) The 52 000 MW Ro/SS-A autoantigen in Sjögren’s syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 106:246–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Rosen A, Casciola-Rosen L (1999) Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 6:6–12

    Article  CAS  PubMed  Google Scholar 

  55. Rosenbaum J, Pottinger BE, Woo P et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Salojin KV, Le Tonquèze M, Saraux A et al (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178–185

    Article  CAS  PubMed  Google Scholar 

  57. Sato S, Fujimoto M, Hasegawa M et al (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41:1123–1133

    Article  CAS  PubMed  Google Scholar 

  58. Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140–146

    Article  CAS  PubMed  Google Scholar 

  59. Sato S, Hayakawa I, Hasegawa M et al (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120:542–547

    Article  CAS  PubMed  Google Scholar 

  60. Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 18:9–17

    Article  CAS  PubMed  Google Scholar 

  61. Sfikakis PP, Tesar J, Baraf H et al (1993) Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92

    Article  CAS  PubMed  Google Scholar 

  62. Sgonc R, Gruschwitz MS, Boeck G et al (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562

    Article  CAS  PubMed  Google Scholar 

  63. Sgonc R, Gruschwitz MS, Dietrich H et al (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Shahin AA, Anwar S, Elawar AH et al (2000) Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function. Rheumatol Int 20:21–24

    Article  CAS  PubMed  Google Scholar 

  65. Strandberg L, Ambrosi A, Espinosa A et al (2008) Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 28:220–231

    Article  CAS  PubMed  Google Scholar 

  66. Tan FK, Zhou X, Mayes MD et al (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694–702

    Article  CAS  Google Scholar 

  67. Tian J, Avalos AM, Mao SY et al (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8:487–496

    Article  CAS  PubMed  Google Scholar 

  68. Torchia D, Caproni M, Volpi W et al (2010) The Fas/Fas ligand system, rather than granzyme B, may represent the main mediator of epidermal apoptosis in dermatomyositis. Clin Exp Dermatol 35:669–670

    Article  CAS  PubMed  Google Scholar 

  69. Urbonaviciute V, Fürnrohr BG, Meister S et al (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 205:3007–3018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Wenzel J, Zahn S, Mikus S et al (2007) The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 157:752–757

    Article  CAS  PubMed  Google Scholar 

  71. Whitfield ML, Finlay DR, Murray JI et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319–12324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Wong D, Kea B, Pesich R et al (2012) Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 7:e29161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Zhou X, Lee JE, Arnett FC et al (2009) HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 60:3807–3814

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Zhou X, Tan FK, Milewicz DM et al (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype”. J Immunol 175:4555–4560

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Yoshihide Asano M.D., Ph.D.

Authors
  1. Yoshihide Asano M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihide Asano M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Kyoto University Grad Sch of Med., Sakyo-ku, Kyoto, Japan

    Kenji Kabashima

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Asano, Y. (2016). Collagen Vascular Disease. In: Kabashima, K. (eds) Immunology of the Skin. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55855-2_31

Download citation

Publish with us

Policies and ethics

Search

Navigation